PETER VALASTRO: Open Payments
NPI 1811529415 · QUEENSBURY, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,312 in 57 payments from 14 companies in 2025. Trend: 2023 $1,239 · 2024 $1,118 · 2025 $1,312
Food & beverage: $1,312
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $253 |
| ABBVIE INC. | 13 | $252 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $137 |
| Lundbeck LLC | 5 | $114 |
| Axsome Therapeutics, Inc. | 5 | $96 |
| Alkermes, Inc. | 3 | $79 |
| Janssen Pharmaceuticals, Inc | 3 | $70 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Neurocrine BioSciences, Inc. | 3 | $65 |
| Novo Nordisk Inc | 2 | $55 |
Products named: CAPLYTA, VRAYLAR, REXULTI, TRINTELLIX, Auvelity, ARISTADA, SPRAVATO, INGREZZA.
Industry payments across NY — which companies pay providers there.
